Beyond Clotting: The Powers of Platelets

Leslie, Mitch

doi:10.1126/science.328.5978.562

Cited by 307 publications

(237 citation statements)

References 0 publications

Supporting

Mentioning

227

Contrasting

Unclassified

Order By: Relevance

“…116 Platelets and endothelial barrier function Recently, much attention has been devoted to addressing the role of platelets in inflammation, and the evolving consensus is that platelets tend to amplify diffrent components of the inflammatory response, most notably the expression of endothelial cell adhesion molecules and the recruitment of leukocytes. 117,118 While there are some reports that describe the ability of platelets to diminish endothelial barrier function, 119 there is a larger body of evidence that supports an anti-permeability effect of platelets. 120 For example, thrombocytopenia appears to elicit an increased vascular permeability in resting microvessels and this response is reversed following the restoration of blood platelet count.…”

Section: Monocytesmentioning

confidence: 99%

Blood cells and endothelial barrier function

2015

View full text Add to dashboard Cite

Section: Monocytesmentioning

confidence: 99%

Blood cells and endothelial barrier function

2015

View full text Add to dashboard Cite

“…(1,2) The platelet is the primary cell for hemostasis and tissue repair, (3) but extensive experimental evidence has also illuminated the involvement of platelets in tumor growth and metastasis. (4)(5)(6) Clinical evidence has demonstrated an association between higher platelet counts (PLTs) and shorter survival time and increased recurrence after treatment in various solid tumors. (7) In terms of HCC, a retrospective analysis using a large database of biopsy-proven HCC patients reported a positive Abbreviations: AFP, alpha-fetoprotein; AUC, area under the curve; CI, confidence interval; GPIIb/IIIa, glycoprotein IIb/IIIa; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HR, hazard ratio; IBI, inflammation-based index; IQR, interquartile range; MELD, Model for End-Stage Liver Disease; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PLT, platelet count; PLT75, platelet count dichotomized at 75 3 10 9 /L; RBC, red blood cell; SMD, standardized mean difference.…”

mentioning

confidence: 99%

Risk of posttransplant hepatocellular carcinoma recurrence is greater in recipients with higher platelet counts in living donor liver transplantation

Han¹,

Lee

Yang

et al. 2017

Liver Transpl

View full text Add to dashboard Cite

Platelets interact with tumor cells and promote metastasis. The importance of platelets in posttransplant hepatocellular carcinoma (HCC) recurrence is unclear. Thus, we aimed to evaluate the association between preoperative platelet count (PLT) and HCC recurrence after living donor liver transplantation. Of 359 recipients of livers from living donors for HCC, 209 of 240 patients who had preoperative PLT £ 75 3 10 9 /L were matched with 97 of 119 patients who had preoperative PLT >75 3 10 9 /L using propensity score matching, with an unfixed matching ratio based on factors such as tumor biology. The cutoff value of 75 3 10 9 /L was set based on optimum stratification analysis. Survival analysis was performed with death as a competing risk event. The primary outcome was overall HCC recurrence. The median follow-up time was 59 months. Before matching, recurrence probability at 1, 2, and 5 years after transplantation was 4.7%, 9.2%, and 11.3% for the low platelet group and 14.5%, 23.0%, and 30.5% for the high platelet group. Recurrence risk was significantly greater in the high platelet group in both univariate (hazard ratio [HR] 5 3.09; 95% confidence interval [CI], 1.86-5.14; P < 0.001) and multivariate analyses (HR 5 2.10; 95% CI, 1.23-3.60; P 5 0.007). In the matched analysis, recurrence risk was also greater in the high platelet group in both univariate (HR 5 2.33; 95% CI, 1.36-4.01; P 5 0.002) and multivariate analyses (HR 5 1.90; 95% CI, 1.02-3.54; P 5 0.04). Preoperative PLT had no interaction with the Milan criteria, alpha-fetoprotein level, Edmonson grade, microvascular invasion, or intrahepatic metastasis. Incorporation of preoperative PLT into the Milan criteria significantly improved predictive power. Inflammation-based scores including neutrophil-tolymphocyte ratio, platelet-to-lymphocyte ratio, and the inflammation-based index did not show superiority to preoperative PLT in predicting HCC recurrence. In conclusion, preoperative PLT appears to be an important host factor affecting HCC recurrence after living donor liver transplantation.Liver Transplantation 24 44-55 2018 AASLD. Liver transplantation is a well-established therapeutic option for treatment of hepatocellular carcinoma (HCC), addressing both underlying liver disease, which is considered a premalignant lesion, and tumor burden. However, many recipients experience tumor recurrence and recurrent HCC is a major cause of death. Thus, better understanding of the contributing factors for HCC metastasis will help improve liver transplant outcome. (1,2) The platelet is the primary cell for hemostasis and tissue repair, (3) but extensive experimental evidence has also illuminated the involvement of platelets in tumor growth and metastasis. (4)(5)(6) Clinical evidence has demonstrated an association between higher platelet counts (PLTs) and shorter survival time and increased recurrence after treatment in various solid tumors. (7) In terms of HCC, a retrospective analysis using a large database of biopsy-proven HCC patients reported a positive Abbrevi...

show abstract

“…Platelets circulate in the bloodstream and respond to vascular lesions (1). In their resting state, they adopt a discoidal shape and have an average lifespan of 5-7 d in humans (2).…”

mentioning

confidence: 99%

Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer

Wang

Stone

Kaelber

et al. 2015

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Thrombocytosis and platelet hyperreactivity are known to be associated with malignancy; however, there have been no ultrastructure studies of platelets from patients with ovarian cancer. Here, we used electron cryotomography (cryo-ET) to examine frozen-hydrated platelets from patients with invasive ovarian cancer (n = 12) and control subjects either with benign adnexal mass (n = 5) or free from disease (n = 6). Qualitative inspections of the tomograms indicate significant morphological differences between the cancer and control platelets, including disruption of the microtubule marginal band. Quantitative analysis of subcellular features in 120 platelet electron tomograms from these two groups showed statistically significant differences in mitochondria, as well as microtubules. These structural variations in the platelets from the patients with cancer may be correlated with the altered platelet functions associated with malignancy. Cryo-ET of platelets shows potential as a noninvasive biomarker technology for ovarian cancer and other platelet-related diseases.electron | cryotomography | platelet | microtubule | cancer

show abstract

Beyond Clotting: The Powers of Platelets

Abstract: Platelets are known for thwarting blood loss, but new research shows these simplified cells defend against microbes and perform other duties—and they're also drug targets in sepsis and other conditions.

Cited by 307 publications

References 0 publications

Blood cells and endothelial barrier function

Blood cells and endothelial barrier function

Risk of posttransplant hepatocellular carcinoma recurrence is greater in recipients with higher platelet counts in living donor liver transplantation

Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer

Contact Info

Product

Resources

About